Palmitoylethanolamide (Pea) for Nerve Function

Research suggests that palmitoylethanolamide (PEA) may support aspects of nerve function, though the evidence is limited and mixed. Two randomized controlled trials examined PEA in the context of neuropathy — one in diabetic patients using a multi-ingredient supplement that included PEA alongside several other compounds, and one in chemotherapy-induced nerve damage using PEA alone — both reporting some improvements in pain and certain nerve conduction measures, while other nerve function parameters showed little to no change. A third study, which examined a genetic mutation affecting anandamide breakdown, offers tangential molecular context but does not directly test PEA's effects on nerve function. Taken together, the available trials are small in scale, and in the multi-ingredient study it is not possible to attribute benefits specifically to PEA, meaning stronger and larger studies isolating PEA's contribution would be needed before firm conclusions can be drawn.